Inactivation of human cystatin C and kininogen by human cathepsin D  by Lenarčič, Brigita et al.
Voh~me 21t(l, namb~r ;L 21 I =21 ~ FEllS 09491 M~reh 1991 
Inactivation ofhuman eystatin C and kininogen by human cat, hepsin D 
Brigita Lenar¢:i~, ~. Marta Kra.~ovee ~, Anka R, itonja t , [sleifur Ohlfsson = and Vito Turk ~ 
D Dfi~rtm¢,t a f  Btuehemt~rry. Jo~=¢f St¢fim h~ttt.l¢, lamovo 39. 6100f7 LJubljtma. Shwen/a, Yu~loM¢tvla and = Drpmime, t t~f Clinieal 
Ch~mtsl~y. Unlr¢~:~lt~ ~fL~ml, Univcrslt, v th~sptml, S.221 85 l.und, 3"wcdcn 
Received i 6 Janultry 1991 
A p~p~ln tnltibitor of 22 kDa was isolated from human pt=te=nta and shown to ~ identical to residues Cy~146.keu:t?.~ of the third domain of 
human klninol~en. This kinino~en dam;tin anti reeon~binan~ hun~an cystatin C were tmtettvated by pcptlde bond eleavalles at hydrophobic amino 
acid residues due to Ihe etClion of cathepsin D, Tlie~e results ftmher support 11~c prop=seal role ofcalhepsin D in the regulation orcysteinc proteinus~ 
activity. 
Cystatin C: KininoJen; Cathepsin D; Prot~inase inhihitor inaetlvation 
1, iNTRODUCTION 
Cathepsin D (EC 3.4.Z3.5) is an aspartic proteinase 
widely distributed in all mammalian tissues (reviewed in 
[1]). The enzyme is located intracellularly, in 
Iysosomes, but has also been detected extracellularly 
under a variety of pathological conditions [2-5]. 
Cathepsin D plays an important role in the degradation 
of  proteins through limited proteolysis. Thus, cathepsin 
D is responsible for the specific cleavage of the myelin 
basic protein [6] and other brain proteins [7], for the 
conversion of proc~llagen to collagen [8], parathyroid 
hormone degradation [9], the release of T-kinin from 
rat T-kininogen [I0,11] and inactivation of human 
stefin A and stefin B, intracellular protein inhibitors of 
cysteine proteinases [12]. 
In this report we show that cathepsin D is able to 
degrade human cystatin C and the third domain of 
kininogen, both extracell.ular protein inhibitors of cys- 
teine proteinases. This finding might be important for 
elucidation of additional e×tracellular actions of 
cathepsin D. 
2. MATERIALS AND METHODS 
2,1 Materials 
Recombinant human cystatin C was prepared as described [13]. 
Human cathepsin D was isolated from spleen [14], Papain (type 111) 
(EC 3,4,22,2) and sttbstrate BANA were from Sigma, Bovine 
haemoglobin was prepared as described in [15]. Pepstatin was from 
Peptide Research Foundation (Osaka, Japan). Acetonitrile and 
t rifluoroacetic acid were from Merck and BDH Chemicals, respec- 
tively. All other chemicals were of analytical grade, 
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2.2 Isnlatlan of thv third don~ain a f  kinhlogc, n 
The isolation was carried out followinj tile procedure as described 
in [161 with some modirietttions. Briefly, human placenta (1000 g) was 
homogenized in 0.9~, NaCI (I :1.5, w/v) sohnlon and centrifuged for 
60 rain a= 14 000 x /~. The supernatant war adjusted to pet 10,$ with 
5 M NaOH, and after standing I h at roan1 temperature, to pH ?.S 
with 3 M HCI, After ¢entrifugation the supernatant was applied to an 
affinity column (7.5 × $.0 era) of Cm-papain-Sepharose 4B prepared 
as in [1"7], et|uilibrated with 10 mM Tris-HCI buffer (pH 7.5). The col- 
untn was washed with the same t~uffer and the bomtd proteins eluted 
tl~en with 10 mM NaOH (pH I 1.01, Papain.inhibitlng fractions were 
pooled, adjusted to pH g.O with 3 M HCI and concentrated by 
ultrafiltration on an YM-5 membrane (Amicon). The concentrated 
sample war dialyzed against 10 mM Tris-HCI buffer (pH 7,5) contain- 
ing 0,1 M NaCI and applied to a column (120 x 5 cm) of Sephadex 
G-75 equilibrated in the same buffer, Papain.inhihiting fractions were 
resolved as three peaks corresponding to M, of about 12 25 attd 6S 
kDa, The 25 kDa.M, protein peak was dialyzed against 10 mM Tris- 
HCI buffer (pH 8,5) at~d subsequently cllromatographed on DEAE- 
Sephacel eq uilibrated with the same buffer, The inhibitor was eluted 
in a single symmetrical peak with linear gradient of NaCI (0,05-0,15 
M) in the same buffer, The sample was concentrated, assayed for its 
purity by SDS-PAGE and amino acid sequence analysis, and stored 
at - 25"C until use, 
2,3. Assays of enzymes and inhibitors 
The inhibitory activity of cystatin C and the third domain of 
kininogen was determined by measuring the inhibition of papain us- 
ing BANA as substrate [18], The cathepsin D activity was measured 
using haemoglobin as substrate [14] and checked by active-site titra- 
tion with pepstatin [19]. Protein concentrations were determined by 
the method of Lowry [20]. One unit of the inhibitor activity was 
defined as the amount which inhibited I /~g of papain completely, 
2.4, The interaction of CPIs with cathepsin D 
The experiment was performed essentially as in [12]. Solutions of 
cystatin C or the third domain of kininogen (2/LM) were mixed with 
an equal volume of cathepsin D (0,5 t~M) in 100 #M sodium acetate 
buffer (pH 3.51 and incubated at 37°0. At various times 100 .1 
samples were removed and the cathepsin D activity was stopped by 
acidifying the samples to pH 2.0 with 3 M HCI, As a control, 
pepstatin (i ~M) was added tO ~athepSi~ D ~tior to incubation. The 
cleavage products were separated by RP-HPLC on Vydac C=~-column 
(250 × 4.6 mm) (10 #m) in a LDC Milton.Roy HPLC using a linear 
gradient of 5-80°70 acetonitrile in O. I °70 trifluoracetic acid. Flow rate 
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was 1,0 ml/min. Peptides were detected by UV.absorption at220 nm, 
collected and dried on a Speed Vac (Savant). 
2.5, Amino acM sequence umtlysis 
Seqt, enc¢ analysis was performed by atttomatic gas-phase Edman 
degradation on an Applied Biosystems sequenalor 470 A [211, tvith 
on.line detection of the released phenylthi0hydantoin derivatives of
amino acids by all Applied Biosystems amino acid analyser 120A [22], 
2,6. Electrophoresis 
SDS gradient PAGE (8-25%) was carried out according to Lacm- 
mli [231, 
3. RESULTS AND DISCUSSION 
3.1. 1solution of the third domain o f  kininogen 
Ion exchange chromatography of the 25 kDa protein 
fractions, obtained from gel chromatography on 
Sephadex G-75, resulted in two major inhibitory peaks 
eluting at 0.04 M NaCI and O. 13 M NaCI, respectively 
(Fig. I). The purity of  both inhibitory peaks was check- 
ed by SDS-PAGE (not shown). The first peak showed 
an apparent Mr o f  25 kDa without prior reduction by 
2-mercaptoethanol whereas an apparent Mr of 13 kDa 
was obtained after reduction (not shown). This 
behaviour corresponds to human stefin B which forms 
an inactive dimer in the absence of  reducing agents [16]. 
The second peak (Fig. I, 3d) was cluted as a 
homogenous protein with Mr of about 22 kDa. The N- 
terminal amino acid sequence analysis of the first 15 
residues revealed that the isolated inhibitor is pure. This 
protein corresponds to the third domain o f  the 
212 
kininogen molecule [24], Th is  fragment starting with 
Cy.~-246 (kininoger~ numbering), was generatedby  
cleavage at lle-245-Cys.246 due to an unknown pro. 
teinase. Similarly, the isolated and sequenced human 
kinmogen fragment of 20 kDa from human synovial 
fluid [25] resulted from the cleavage at position 
Thr-243-Lys-244 o f  tile kininogen. These two 
fragments derived frona the junction of  the second and 
the third cystatin-like domain, constituting the 
kininogen heavy chain, This junction represents one of 
the proteinase-sensitive r gions in the kininogen 
molecule [24,26], 
3,2, Fragmentation of human cystatin C and the third 
domain of kininogen by cathepsin D 
Incubation of cystatin C and the kininogen domain 
with cathepsin D resulted in rapid fragmentation of 
both protein inhibitors. Prolonged incubation up to 45 
rain resulted in additional fragments. These fragments 
were separated by RP .HPLC (Fig. 2) and subjected to 
NH2-terminal sequence analysis. Points of  cleavages 
for human cystatin C and the third domain of 
kininogen are presented in Fig. 3. Cathepsin D 
preferentially cleaved hydrophobic residues, one often 
being aromatic. When digestion was performed at pH 
5.0, otherwise under identical e×perimental conditions 
the same fragments were obtained (data not shown), 
although the rate was significantly slower. This pH cor- 
responds to that of lysosomes [27]. Degradation of  both 
protein inhibitors was inhibited completely when 
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Fig, 2, RP-HPLC of  peptides released from cystatin C and the third domain  o f  klninogen after incubation with cathepsin D. (A) cystatin C (c¢) 
after I rain of  incubation; (B) cystatin C (co) after 40 rain of  incubation; (C) third domain of  kininogen (3d) after 30 s of  incubation; (D) third 
domain of kininogen (3d} after 40 rain of incubation; ( - - )  absorbancy A220; (- - -) acetonitrile, Volume of 100 ~I of reaction mixture was injected 
into the reverse-phase column. Major peaks are marked and their positions in the sequences are indicated in Fig, 3. 
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Fig, 3. Action of human cathepsin D On cystatln C (a) and the third domain of kininogen (b). (,I.) Major sites of cleavage; ( v ) additional cleavage 
sites. C0ntinuous lines indicates regions of' peptide sequenced in cystatin C (a, b, c, d, e, f, g, h, i) and in the tlfird domain of kininogen (j, k, 
I, m, n, o, p, r), 
pepstatin [2 ~M] was added, prior to the inhibitors, tO . . . .  tah led recently after CNBr cleavage of chicken cystatin 
the incubation rni×ture (results not shown). This in- [30]. Cleavage by cathepsin D inactivates most of the in. 
dicaies•that the cleavages were generated by cathepsin hibitory activity of the cysteine proteinase inhibitors. 
D. The proteolytic fragments obtained after interaction Consequently, limited proteolysis of cystatins by this 
with cathepsin D did not show inhibitory activity on pa- action indicates a possible physiological role for cathep- 
pain. The exception were both peptides containing sin D in the regulation of cysteine proteinase activities. 
residues 55-59 in cystatin C and the corresponding Inactivation of CPIs by the aspartic proteinase cathep- 
region in the kininogen domain. This region has been sin D is important since we would not expect the cys- 
identified as important in the binding to proteinases teine proteinases of lysosomes to inactivate them. 
[28,29]. gi values were above 10- 6 M indicating a great- Specifically, it is known that the interaction of CPIs 
ly decreased binding. However, a similar inhibitory with ttieir target enzymes does not lead to peptide bond 
peptide containing this regions with similar Kls was ob- cleavage [29,31]. 
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